CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive MetabolizersS

被引:2
|
作者
Czuba, Lindsay C. [1 ]
Malhotra, Karan [2 ]
Enthoven, Luke [2 ]
Fay, Emily E. [3 ]
Moreni, Sue L. [3 ]
Mao, Jennie [3 ]
Shi, Yuanyuan [4 ]
Huang, Weize [1 ]
Totah, Rheem A. [4 ]
Isoherranen, Nina [1 ]
Hebert, Mary F. [2 ,3 ,5 ,6 ]
机构
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA USA
[2] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA USA
[4] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA USA
[5] Univ Washington, Dept Pharm, Pharm, H-375 Hlth Sci Ctr,1959 NE Pacific St,POB 357630, Seattle, WA 98195 USA
[6] Univ Washington, Dept Pharm, Obstet & Gynecol, H-375 Hlth Sci Ctr,1959 NE Pacific St,POB 357630, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
SMALL HETERODIMER PARTNER; BILE-ACID; AMINO-ACID; EXPRESSION; FXR;
D O I
10.1124/dmd.123.001358
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of > 20% of marketed drugs. CYP2D6 expression and activity exhibit high interindividual variability and is induced during pregnancy. The farnesoid X receptor (FXR) is a transcriptional regulator of CYP2D6 that is activated by bile acids. In pregnancy, elevated plasma bile acid concentrations are associated with maternal and fetal risks. However, modest changes in bile acid concentrations may occur during healthy pregnancy thereby altering FXR signaling. A previous study demonstrated that hepatic tissue concentrations of bile acids positively correlated with the hepatic mRNA expression of CYP2D6. This study sought to characterize the plasma bile acid metabolome in healthy women (n=47) during mid-pregnancy (25-28 weeks gestation) and {greater than or equal to} 3 months postpartum, and to determine if plasma bile acids correlate with CYP2D6 activity. It is hypothesized that during pregnancy plasma bile acids would favor less hydrophobic bile acids (cholic acid vs. chenodeoxycholic acid), and that plasma concentrations of cholic acid and its conjugates would positively correlate with the urinary ratio of dextrorphan / dextromethorphan. At 25-28 weeks gestation, taurine conjugated bile acids comprised 23% of the quantified serum bile acids compared to 7% {greater than or equal to} 3 months postpartum. Taurocholic acid positively associated with the urinary ratio of dextrorphan / dextromethorphan, a biomarker of CYP2D6 activity. Collectively, these results confirm that the bile acid plasma metabolome differs between pregnancy and postpartum and provide evidence that taurocholic acid may impact CYP2D6 activity during pregnancy.
引用
收藏
页码:1474 / 1482
页数:9
相关论文
共 50 条
  • [31] CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene
    Skierka, Jennifer M.
    Walker, Denise L.
    Peterson, Sandra E.
    O'Kane, Dennis J.
    Black, John Logan, III
    PHARMACOGENOMICS, 2012, 13 (08) : 951 - 954
  • [32] GENETIC POLYMORPHISM IN CYTOCHROME P450 2D6 (CYP2D6): POPULATION DISTRIBUTION OF CYP2D6 ACTIVITY
    Neafsey, Patricia
    Ginsberg, Gary
    Hattis, Dale
    Sonawane, Babasaheb
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2009, 12 (5-6): : 334 - 361
  • [33] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
  • [34] Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
    Charoenchokthavee, Wanaporn
    Panomvana, Duangchit
    Sriuranpong, Virote
    Areepium, Nutthada
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 149 - 155
  • [35] The interaction of terfenadine with CYP2D6
    Jones, BC
    Hyland, R
    Ackland, M
    Tyman, CA
    Smith, DA
    FASEB JOURNAL, 2000, 14 (08): : A1503 - A1503
  • [36] Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population
    Cai, W. M.
    Chen, B.
    Zhang, W. X.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (01) : 95 - 98
  • [37] The CYP2D6 VCF Translator
    Qiao, W.
    Wang, J.
    Pullman, B. S.
    Chen, R.
    Yang, Y.
    Scott, S. A.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (04): : 301 - 303
  • [38] The CYP2D6 VCF Translator
    W Qiao
    J Wang
    B S Pullman
    R Chen
    Y Yang
    S A Scott
    The Pharmacogenomics Journal, 2017, 17 : 301 - 303
  • [39] Understanding CYP2D6 interactions
    de Groot, Marcel J.
    Wakenhut, Florian
    Whitlock, Gavin
    Hyland, Ruth
    DRUG DISCOVERY TODAY, 2009, 14 (19-20) : 964 - 972
  • [40] CYP2D6, serotonin and suicide
    Ahlner, Johan
    Zackrisson, Anna-Lena
    Lindblom, Bertil
    Bertilsson, Leif
    PHARMACOGENOMICS, 2010, 11 (07) : 903 - 905